VERRICA PHARMACEUTICALS INC (VRCA) Stock Price, Quote, News and Overview
NASDAQ:VRCA - Nasdaq - US92511W1080 - Common Stock - Currency: USD
VRCA Quote, Performance and Key Statistics
NASDAQ:VRCA (8/8/2025, 8:11:27 PM)
6.35
+0.24 (+3.93%)
The current stock price of VRCA is 6.35 USD. In the past month the price decreased by -21.27%. In the past year, price decreased by -87.22%.
VRCA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 38.74 | 592.95B | ||
| JNJ | JOHNSON & JOHNSON | 17.33 | 417.44B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.57 | 228.04B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.96 | 226.97B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.2 | 226.19B | ||
| MRK | MERCK & CO. INC. | 10.48 | 202.62B | ||
| PFE | PFIZER INC | 7.25 | 139.75B | ||
| SNY | SANOFI-ADR | 10.66 | 114.95B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.83 | 93.51B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 76.27B | ||
| ZTS | ZOETIS INC | 23.69 | 65.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.79 | 45.60B |
Related stock screener links
About VRCA
Company Profile
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Company Info
VERRICA PHARMACEUTICALS INC
10 N High St Ste 200
West Chester PENNSYLVANIA 19380 US
CEO: Ted White
Employees: 71
Phone: 14844533300
VERRICA PHARMACEUTICALS INC / VRCA FAQ
What is the stock price of VERRICA PHARMACEUTICALS INC today?
The current stock price of VRCA is 6.35 USD. The price increased by 3.93% in the last trading session.
What is the ticker symbol for VERRICA PHARMACEUTICALS INC stock?
The exchange symbol of VERRICA PHARMACEUTICALS INC is VRCA and it is listed on the Nasdaq exchange.
On which exchange is VRCA stock listed?
VRCA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERRICA PHARMACEUTICALS INC stock?
11 analysts have analysed VRCA and the average price target is 40.8 USD. This implies a price increase of 542.52% is expected in the next year compared to the current price of 6.35. Check the VERRICA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERRICA PHARMACEUTICALS INC worth?
VERRICA PHARMACEUTICALS INC (VRCA) has a market capitalization of 58.74M USD. This makes VRCA a Micro Cap stock.
How many employees does VERRICA PHARMACEUTICALS INC have?
VERRICA PHARMACEUTICALS INC (VRCA) currently has 71 employees.
What are the support and resistance levels for VERRICA PHARMACEUTICALS INC (VRCA) stock?
VERRICA PHARMACEUTICALS INC (VRCA) has a support level at 5.67 and a resistance level at 6.36. Check the full technical report for a detailed analysis of VRCA support and resistance levels.
Is VERRICA PHARMACEUTICALS INC (VRCA) expected to grow?
The Revenue of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 138.35% in the next year. Check the estimates tab for more information on the VRCA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERRICA PHARMACEUTICALS INC (VRCA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRCA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRCA, evaluating the profitability, health, valuation and growth aspects
- VERRICA PHARMACEUTICALS INC (VRCA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERRICA PHARMACEUTICALS INC (VRCA) Sales and EPS estimates to see what analysts future expectations are.
- VERRICA PHARMACEUTICALS INC (VRCA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERRICA PHARMACEUTICALS INC (VRCA) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERRICA PHARMACEUTICALS INC (VRCA) Stock Chart to make your own analysis
- VERRICA PHARMACEUTICALS INC (VRCA) Latest news and press-releases to stay up to date.
Does VERRICA PHARMACEUTICALS INC (VRCA) stock pay dividends?
VRCA does not pay a dividend.
When does VERRICA PHARMACEUTICALS INC (VRCA) report earnings?
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2025-08-12, after the market close.
What is the Price/Earnings (PE) ratio of VERRICA PHARMACEUTICALS INC (VRCA)?
VERRICA PHARMACEUTICALS INC (VRCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.26).
VRCA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VRCA. When comparing the yearly performance of all stocks, VRCA is a bad performer in the overall market: 89.64% of all stocks are doing better.
VRCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VRCA. Both the profitability and financial health of VRCA have multiple concerns.
VRCA Financial Highlights
Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -4.26. The EPS decreased by -143.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -156.46% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VRCA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to VRCA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 91.94% and a revenue growth 138.35% for VRCA